Asia · Markets & Finance · Vietnam Investment Review

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

Published by Vietnam Investment Review · Vietnam 8 h ago

Biopharmaceutical firm CSL paid 355 million US dollars upfront to Alentis to commercialise lixudebart, pledging up to 1.2 billion US dollars in milestone payments for rare disease…

Read the full article on Vietnam Investment Review Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)

Also worth reading

The Business Times

DBS tops trades in smaller board lots on debut of revised SGX framework

The Straits Times Business

Selected 11 stocks see immediate uptake of smaller board lot sizes on SGX

CNBC-TV18

Sensex Today | Stock Market Highlights: Market ends higher for 2nd straight day; Nifty reclaims 22,700

Mint

Why Kotak Mahindra Bank shares are outperforming Nifty 50 and Bank Nifty in the last two months? Experts explain

The Economic Times

More about the Nobel prize winner in Physics

Tech in Asia